Loading
Journal of Clinical Haematology
ISSN: 2766-4686
HiDAC Consolidation Cycles May Impede Stem Cell Transplant Planning for High-Risk Acute Myeloid Leukemia Patients
Introduction: For patients with high-risk acute myeloid leukemia (AML), defined by certain cytogenetic (CG) and molecular genetic features, hematopoietic stem cell transplantation (HSCT) remains the only curative therapy. The logistics of proceeding to transplant might necessitate consolidation chemotherapy involving high dose cytarabine (HiDAC).
J Clin Haematol, 2026, Volume 7, Issue 1, p1-12 | DOI: 10.33696/haematology.7.073
Bispecific Antibodies and CAR-T cell Therapy in Multiple Myeloma
Triple class exposed patients with multiple myeloma (MM) represent an unmet need with outcomes remaining poor with those with relapsed/refractory multiple myeloma (RRMM) having a mere 29.8% overall response rate and 12.4-month median overall survival. We explore emerging strategies focusing on bispecific antibodies and CAR-T cell therapies for treatment of refractory myeloma.
J Clin Haematol, 2026, Volume 7, Issue 1, p13-18 | DOI: 10.33696/haematology.7.074
Hematology and Blood Transfusion: An Indispensable Pillar of Medical Laboratory Science
Hematology and Blood Transfusion constitute one of the most distinctive and indispensable units within Medical Laboratory Science, underpinning a wide spectrum of clinical decision-making and lifesaving interventions. Discipline occupies a unique position in healthcare delivery by directly linking laboratory diagnostics with patient prognosis, therapeutic monitoring, and emergency management. Without robust hematology and transfusion services, modern clinical practice would be fundamentally compromised.
J Clin Haematol, 2026, Volume 7, Issue 1, p19-20 | DOI: 10.33696/haematology.7.075
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.